The conference call can be accessed using the following information: Webcast: Click here Date: Wednesday, August 13, 2025 – 4:30 p.m. ET Domestic: (877) 407-0832 International: (201) 689-8433 ...

CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following ...

“We’re thrilled to welcome Dr. Tarnoff to our Board during this pivotal phase of growth,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “His leadership and expertise in clinical ...

Third quarter fiscal 2025 revenue up 23.5% to $130.7 million – Year-to-date fiscal 2025 revenue increased 4.0% to $374.9 million – Conference call scheduled for today at 4 ...

Total revenue of $8.5 million in the second quarter of 2025, a decrease of 18% over the second quarter of 2024. MaxCyte added two new SPL clients, Adicet Bio and Anocca AB, in July. Including TG ...

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...

Second quarter 2025 selling, general and administrative expenses increased by $0.7 million year-over-year, to $9.7 million (from $9.0 million). The increase was primarily driven by higher sales ...

Net loss was $19.6 million for the second quarter of 2025, compared to a loss of $25.6 million in the prior year period. Adjusted EBITDA was a loss of $8.0 million for the second quarter of 2025, ...

Conference Call and Webcast scheduled for tomorrow, August 7, 2025 at 10:00 am MT. EAGLE, Idaho, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the pare ...

REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

Research and development expenses were $16.1 million for the three months ended June 30, 2025, compared to $16.3 million for the same period in 2024. The decrease is most largely due to a decrease in ...